Open access · US-GOV via ClinicalTrials.gov Clinical trial

The Effect of Vascular Distensibility on Endothelial-Dependent Vasoreactivity in Patients With Systolic Hypertension Before and After Receiving Oral Alagebrium for 8 Weeks.

Authors not listed

Synvista Therapeutics, Inc · 2004

Deregulated nutrient-sensing Exercise Human Randomized controlled trial

Abstract

Determine whether increasing arterial distensibility by decreasing advanced glycation end-product (AGE) cross-link components of vascular stiffness improves (a) endothelial-mediated vasoreactivity at rest, as assessed by flow-mediated vasodilation (FMD), and (b) endothelial-mediated vasoreactivity after exercise, as assessed by pulse perfusion-mediated vasodilation (PPMV).

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-21 MST

Cite this

APA

Anonymous. (2004). The Effect of Vascular Distensibility on Endothelial-Dependent Vasoreactivity in Patients With Systolic Hypertension Before and After Receiving Oral Alagebrium for 8 Weeks. <em>Synvista Therapeutics, Inc</em>. https://clinicaltrials.gov/study/NCT00277875

Vancouver

Anonymous. The Effect of Vascular Distensibility on Endothelial-Dependent Vasoreactivity in Patients With Systolic Hypertension Before and After Receiving Oral Alagebrium for 8 Weeks. Synvista Therapeutics, Inc. 2004.

BibTeX

@misc{anon2004TheEff, title = {The Effect of Vascular Distensibility on Endothelial-Dependent Vasoreactivity in Patients With Systolic Hypertension Before and After Receiving Oral Alagebrium for 8 Weeks.}, author = {Anonymous}, journal = {Synvista Therapeutics, Inc}, year = {2004}, }